株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヒトマイクロバイオーム治療薬の世界市場の分析・予測 (2019-2029年)

Global Human Microbiome Therapeutics Market Forecast 2019-2029: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders

発行 Visiongain Ltd 商品コード 863491
出版日 ページ情報 英文 250 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.81円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
ヒトマイクロバイオーム治療薬の世界市場の分析・予測 (2019-2029年) Global Human Microbiome Therapeutics Market Forecast 2019-2029: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders
出版日: 2019年04月24日 ページ情報: 英文 250 Pages
概要

世界のヒトマイクロバイオーム治療薬の市場は予測期間前半において60.2%のCAGR (年間複合成長率) を記録し、2024年には10億ドルの規模に成長すると予測されています。

当レポートでは、世界のヒトマイクロバイオーム治療薬の市場を調査し、ヒトマイクロバイオームの概要、ヒトマイクロバイオーム治療薬と対象疾患における重要性、疾患区分・地域/主要国別の動向と市場規模の推移と予測、主要企業・主要製品のプロファイルなどをまとめています。

第1章 レポート概要

第2章 イントロダクション:ヒトマイクロバイオーム

  • 医薬品産業の概要
  • 健康とヒトマイクロバイオータ
  • 疾患とヒトマイクロバイオータ
  • 開発中のマイクロバイオームプロジェクト
  • 治療薬としてのマイクロバイオームの課題
  • アンメットニーズ

第3章 ヒトマイクロバイオーム関連疾患による負担

第4章 ヒトマイクロバイオーム治療薬

  • 胃腸障害
    • 分類
    • マイクロバイオータの役割
  • 感染症
    • 分類
    • マイクロバイオータの役割
  • 代謝性疾患・肝臓疾患
    • 分類
    • マイクロバイオータの役割
  • 皮膚疾患
    • 分類
    • マイクロバイオータの役割

第5章 臨床試験のフェーズ

第6章 ヒトマイクロバイオーム治療薬:市場の定義

  • 市場概要・推移
  • 市場予測
  • 市場シェアの変化の見通し

第7章 ヒトマイクロバイオーム治療薬市場の分析・予測:疾患区分別

  • 胃腸障害
  • 感染症
  • 代謝性疾患
  • 皮膚疾患
  • その他 (心血管・CNS・癌)

第8章 市場の潜在性:疾患区分別

  • 胃腸障害
  • 感染症
  • 代謝性疾患
  • 皮膚疾患
  • その他

第9章 市場分析・予測:主要国別

  • ヒトマイクロバイオーム治療薬市場:地域別
  • 主要国市場の予測
  • 米国
  • EU5カ国
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
  • 日本
  • その他の地域

第10章 主要企業

  • 4D Pharma Plc.
  • Synthetic Biologics
  • Seres Therapeutics
  • Ferring Pharmaceuticals
  • AOBiome Therapeutics
  • Osel Inc.,
  • Immuron Ltd
  • Ritter Pharmaceuticals, Inc.
  • Intrexon Corporation
  • Synlogic
  • C3J Therapeutics
  • Finch Therapeutics/Crestovo
  • MaaT Pharma
  • IGEN BIOTECH GROUP
  • MatriSys Biosystem
  • Second Genome
  • Microbiome Therapeutics LLC
  • Caelus Health
  • Enterome Bioscience
  • Vedanta Biosciences

第11章 主要製品:胃腸障害

  • RBX2600 & RBX7455:Ferring Therapeutics
  • SER-109, SER287 & SER-262:Seres Therapeutics
  • Ribaxamase & SYN-010:Synthetic Biologics
  • IMM-529:Immuron
  • SGM-1019:Second Genome
  • Blautix, Thetanix & Rosburix:4D Pharma
  • EB8018:Enterome Bioscience

第12章 主要製品:代謝性疾患

  • RP-G28:Ritter Therapeutics
  • IMM-124E:Immuron
  • CP-001:Caelus Health
  • NM504 & NM505:Microbiome Therapeutics
  • SYNB1020:Synlogic

第13章 主要製品:感染症

  • LACTIN-V:Osel
  • AOB-201:AOBiome Therapeutics
  • MaaT001:MaaT Pharma
  • CBM588:Osel Inc.

第14章 主要製品:皮膚疾患

  • AOB101, AOB102 & AOB103:AOBiome Therapeutics
  • MSB-01 & MSB-03:MatriSys Biosystem

第15章 主要製品:その他

  • AG013:Intrexon
  • AOB202 & AOB 203:AOBiome Therapeutics
  • C16G2:C3J Therapeutics
  • Microbiome Modulators:IGEN BIOTECH

第16章 定性分析

第17章 総論

図表

List of Tables

  • Table 4.1: Skin Disease and Related Microbiota
  • Table 5.1: Clinical Trial Phases
  • Table 6.1: Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020
  • Table 6.2: Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Table 6.3: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector
  • Table 6.4: Global Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2020, 2024, 2029
  • Table 7.1: Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029
  • Table 7.2: Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029
  • Table 7.3: Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m, AGR% and CAGR%), 2019-2029
  • Table 7.4: Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m, AGR% and CAGR%), 2019-2029
  • Table 7.5: Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m, AGR% and CAGR%), 2019-2029
  • Table 9.1: Global Human Microbiome Therapeutics Market: Market Size ($m) and Market Share (%) by Region, 2021
  • Table 9.2: Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029
  • Table 9.3: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
  • Table 9.4: Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021, 2024, and 2029
  • Table 9.5: The US Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.6: US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.7: The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Table 9.8: The United States Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
  • Table 9.9: EU5 Human Microbiome Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2019-2029
  • Table 9.10: EU5 Human Microbiome Drugs Market: Revenue ($m), and Market Share (%) by Country, 2021
  • Table 9.11: EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), by Country, 2019-2029
  • Table 9.12: EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021, 2024, 2029
  • Table 9.13: EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Table 9.14: EU5 Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
  • Table 9.15: German Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2021-2029
  • Table 9.16: German Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.17: The French Human Microbiome Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.18: French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.19: The UK Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.20: UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.21: Italian Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.22: Italian Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.23: Spanish Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.24: Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.25: Japanese Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.26: Japanese Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.27: Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Table 9.28: Japan Human Microbiome Therapeutics Market: Revenue ($m) and Market Share (%) by Sector, 2021, 2024, 2029
  • Table 9.29: The Rest of the World Human Microbiome Therapeutics Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 9.30: Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 10.1: Pipeline Therapeutics by Companies
  • Table 10.2: 4D Pharma: Company Overview, 2018
  • Table 10.3: 4D Pharma: Key Pipeline Products, 2018
  • Table 10.4: Synthetic Biologics: Company Overview, 2018
  • Table 10.5: Synthetic Biologics: Key Pipeline Products, 2018
  • Table 10.6: Seres Therapeutics: Company Overview, 2018
  • Table 10.7: Clinical Trials Description
  • Table 10.8: Clinical Trials Description
  • Table 10.9: Clinical Trials Description
  • Table 10.10: Seres Therapeutics: Key Pipeline Products, 2018
  • Table 10.11: Ferring Pharmaceuticals: Company Overview, 2018
  • Table 10.12: Clinical Trials Description
  • Table 10.13: Clinical Trials Description
  • Table 10.14: Ferring Pharmaceuticals: Key Pipeline Products, 2018
  • Table 10.15: AOBiome, LLC: Company Overview, 2018
  • Table 10.16: Clinical Trials Description
  • Table 10.17: AOBiome Therapeutics: Key Pipeline Products, 2018
  • Table 10.18: Osel Inc: Company Overview, 2018
  • Table 10.19: Clinical Trials Description
  • Table 10.20: Osel Inc: Key Pipeline Products, 2018
  • Table 10.21: Immuron Ltd: Company Overview, 2018
  • Table 10.22: Clinical Trials Description
  • Table 10.23: Clinical Trials Description
  • Table 10.24: Key Pipeline Products, 2018
  • Table 10.25: Ritter Pharmaceuticals, Inc.: Company Overview, 2018
  • Table 10.26: Clinical Trials Description
  • Table 10.27: Ritter Pharmaceuticals: Key Pipeline Products, 2018
  • Table 10.28: Intrexon Corporation: Company Overview, 2018
  • Table 10.29: Clinical Trials Description
  • Table 10.30: Intrexon: Key Pipeline Products, 2018
  • Table 10.31: Synlogic: Company Overview, 2018
  • Table 10.32: Synlogic: Key Pipeline Products, 2018
  • Table 10.33: C3J Therapeutics: Company Overview, 2018
  • Table 10.34: Clinical Trials Description
  • Table 10.35: C3J Therapeutics: Key Pipeline Products, 2018
  • Table 10.36: Finch Therapeutics: Company Overview, 2018
  • Table 10.37: Clinical Trials Description
  • Table 10.38: Finch/Crestovo: Key Pipeline Products, 2018
  • Table 10.39: MaaT Pharma: Company Overview, 2018
  • Table 10.40: Clinical Trials Description
  • Table 10.41: IGEN BIOTECH GROUP: Company Overview, 2018
  • Table 10.42: IGEN BIOTECH: Key Pipeline Products
  • Table 10.43: MatriSys Biosystem: Company Overview, 2018
  • Table 10.44: MatriSys Biosystem: Key Pipeline Products, 2018
  • Table 10.45: Second Genome: Company Overview, 2018
  • Table 10.46: Second Genome: Key Pipeline Products, 2018
  • Table 10.47: Microbiome Therapeutics: Company Overview, 2018
  • Table 10.48: Clinical Trials Description
  • Table 10.49: Microbiome Therapeutics: Key Pipeline Products, 2018
  • Table 10.50: Caelus Health: Company Overview, 2018
  • Table 10.51: Key Pipeline Products, 2018
  • Table 10.52: Enterome Bioscience: Company Overview, 2018
  • Table 10.53: Clinical Trials Description
  • Table 10.54: Enterome Bioscience: Key Pipeline Products, 2018
  • Table 10.55: Vedanta Biosciences: Company Overview, 2018
  • Table 10.56: Vedanta Biosciences: Key Pipeline Products, 2018
  • Table 11.1: Gastrointestinal Disorders Drugs Pipeline: Key Drugs, 2018
  • Table 12.1: Metabolic Disorders Drugs Pipeline, 2018
  • Table 13.1: Infectious Disease Drugs Pipeline: Key Products, 2018
  • Table 14.1: Dermatological Disorders Drugs Pipeline: Key Products, 2018
  • Table 15.1: Other Disorders Drugs Pipeline: Key Products, 2018
  • Table 16.1: SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029
  • Table 16.2: World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
  • Table 17.1: Global Human Microbiome Therapeutics: Market Forecast ($m, CAGR%), 2020, 2024 and 2029
  • Table 17.2: The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2020, 2024, 2029

List of Figures

  • Figure 1.1: Global Human Microbiome Therapeutics Market: Market Sectors
  • Figure 2.1: Role of Human Microbiota in Various Diseases
  • Figure 6.1: Global Human Microbiome Therapeutics Market: Revenue ($m) by Sector, 2020
  • Figure 6.2: Global Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 6.3: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Sector, 2024-2029
  • Figure 6.4: Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2020
  • Figure 6.5: Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 6.6: Global Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
  • Figure 7.1: Global Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Market Forecast ($m), 2019-2029
  • Figure 7.2: Global Human Microbiome Therapeutics Market for Infectious Diseases: Market Forecast ($m), 2019-2029
  • Figure 7.3: Global Human Microbiome Therapeutics Market for Metabolic Diseases: Market Forecast ($m), 2019-2029
  • Figure 7.4: Global Human Microbiome Therapeutics Market for Dermatological Conditions: Market Forecast ($m), 2019-2029
  • Figure 7.5: Global Human Microbiome Therapeutics Market for Other Disorders: Market Forecast ($m), 2019-2029
  • Figure 9.1: Global Human Microbiome Therapeutics Market: Market Size ($m) by Region, 2021
  • Figure 9.2: US, EU, Japan and ROW Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
  • Figure 9.3: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region
  • Figure 9.4: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2024-2029
  • Figure 9.5: Global Human Microbiome Therapeutics Market Forecast: CAGR (%) by Region, 2021-2029
  • Figure 9.6: Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2021
  • Figure 9.7: Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2024
  • Figure 9.8: Global Human Microbiome Therapeutics Market Forecast: Market Share (%) by Region, 2029
  • Figure 9.9: US Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 9.10: The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Figure 9.11: The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 9.12: The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.13: The United States Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
  • Figure 9.14: EU5 Human Microbiome Drugs Market: Revenue ($m) by Country, 2021
  • Figure 9.15: Germany, France, UK, Italy, and Spain Human Microbiome Drugs Market: Market Forecast ($m), 2019-2029
  • Figure 9.16: EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2021
  • Figure 9.17: The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2024
  • Figure 9.18: The EU5 Human Microbiome Therapeutics Market: Market Share (%) by Country, 2029
  • Figure 9.19: EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Figure 19.2: EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2021
  • Figure 19.2: EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 19.2: EU5 Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
  • Figure 9.23: German Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
  • Figure 9.24: French Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 9.25: UK Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 9.26: Italian Human Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 9.27: Spanish Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 9.28: Japanese Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
  • Figure 9.29: Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Figure 9.30: Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2024
  • Figure 9.31: Japan Human Microbiome Therapeutics Market: Market Share (%) by Sector, 2029
  • Figure 9.32: Rest of the World Human Microbiome Therapeutics Market: Market Forecast ($m), 2019-2029
  • Figure 17.1: Global Human Microbiome Therapeutics: Market Forecast ($m), 2019- 2029
  • Figure 17.2: The Global Human Microbiome Therapeutics Market: Market Forecast ($m) by Region, 2019-2029

COMPANIES LISTED:

  • 4D Pharma
  • 4D Pharma Cork Limited
  • 4D Pharma Leon
  • AbbVie S.à.r.l.
  • Accinov
  • ActoGeniX
  • Aju IB Investment
  • Ally Bridge Group
  • Amrita Therapeutics
  • AOBiome, LLC
  • AquaBounty Technologies
  • Arctic Aurora Life Science
  • Aspire Capital Fund
  • Assembly Biosciences
  • Azitra
  • BaseClear
  • BIOASTER
  • Biological & Popular Culture, Inc.
  • BiomX
  • Bio-Technology General
  • Blue Turtle Bio
  • Bristol-Myers Squibb
  • BYTC Corp
  • C3J Therapeutics
  • Caelus Health
  • Cd4 Biosciences, Inc.
  • Cedars-Sinai Medical Centre
  • Chengdu Sen Nuo Wei Biotechnology Co., Ltd
  • CLI Ventures
  • Codexis Laboratories Hungary Kft
  • CoreBiome
  • Crestovo
  • CRS Bio, Inc
  • DayTwo
  • Digitalis Ventures
  • Effective Pharmaceuticals, Inc.
  • Enterome Bioscience
  • Enterome SA
  • EnviroFlight, LLC
  • Epibiome
  • Epitope Pharmaceuticals, Inc.
  • Evelo Biosciences
  • Evolve BioSystems
  • Ferring Pharmaceuticals
  • Ferring Sas
  • Finch Therapeutics Group, Inc.
  • Finch Therapeutics
  • Genomatix Ltd.
  • Genten Therapeutics, Inc.
  • GenVec, Inc.
  • Global Bioscience Company
  • GT Biologics Limited
  • Hartlab LLC
  • Harvest Capital Strategies, LLC
  • HealthMine, Inc
  • IBBL
  • iCarbonX
  • Igen Biotech Group
  • ImmuneBiotech AB
  • Immuron, Ltd.
  • INC Research
  • INRA transfer
  • Intrexon
  • Intrexon Actobiotics N.V.
  • Intrexon Corporation
  • Intrexon Crop Protection
  • Intrexon Energy Partners II, LLC
  • Intrexon Energy Partners, LLC
  • Intrexon T1D Partners
  • Janssen Biotech
  • Johnson & Johnson
  • Kallyope
  • Kolu Pohaku Management, LLC
  • Kolu Pohaku Technologies
  • Leading Biosciences
  • LNC Therapeutics
  • Lundbeckfond Ventures
  • MaaT Pharma SA
  • MatriSys Bioscience
  • MatriSys Biosystem
  • Mayo Clinic
  • Medistem, Inc.
  • Medpace
  • Merck & Co., Inc.
  • Microbiome Therapeutics, LLC
  • Microbiomics Limited
  • Mirna Therapeutics
  • Nestle Health Science
  • Nitrocell
  • NIZO
  • Nubiyota
  • NuMe Health LLC
  • Okanagan Specialty Fruits Inc.
  • Omnes Capital
  • OpenBiome
  • OptiBiotix Health plc
  • OrbiMed HealthCare Fund Management
  • Osel, Inc.
  • OvaXon, LLC
  • Oxitec
  • Perceptive Advisors
  • Pfizer Venture Investments
  • Pharm-Olam International
  • Pipex Therapeutics, Inc
  • Precigen, Inc.
  • Prev AbR LLC
  • ProDigest
  • PureTech Health
  • Putney Drug Corp
  • Pylum Biosciences
  • Quorum Innovations
  • Rebiotix, Inc
  • Ritter Natural Sciences, LLC
  • Ritter Pharmaceuticals
  • Roche Venture Fund
  • Rock Springs Capital
  • S & I Ophthalmic
  • S-Biomedic
  • Second Genome
  • Seres Therapeutics
  • Seventure Partners
  • Shire
  • Solovax, Inc
  • SR One Venture Partners
  • Symberix
  • Symbiotic Health
  • Symbiotix Biotherapies
  • Synlogic, Inc.
  • Synthetic Biologics, Inc.
  • Synthetic Biomics Inc.
  • Synthetic Genomics, Inc.
  • Takeda
  • TargEDys
  • Tech Coast Angels (TCA)
  • The Microbiota Company Limited
  • Trans Ova Genetics LC
  • Tucana Health Limited
  • Vedanta Biosciences Inc.
  • Veristat
  • Vertex Pharmaceuticals Inc.
  • Whole Biome
  • Xycrobe Therapeutics

List of Organizations Mentioned in the Report:

  • Alimentary Pharmabiotic Centre
  • American Academy of Dermatology
  • APC Microbiome Institute
  • Central Drugs Standard Control Organisation (CDSCO)
  • French National Institute for Agricultural Research
  • Hadasit Medical Research Services & Development Ltd
  • Hadassah Medical Center
  • Health Canada
  • Institut National de la Recherche Agronomique
  • Integrium
  • John Theurer Cancer Center of Hackensack Meridian Health
  • King's College London
  • La Trobe University
  • Lawrence Berkeley National Laboratory
  • Leiden University Medical Center
  • Mayo clinic
  • Medicines Control Council (MCC)
  • Medical University of Graz
  • Memorial Sloan Kettering Cancer Center
  • Ministry of Health, Labour and Welfare (MHLW)
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Microbiome Institute at University College Cork
  • Monash University
  • Murdoch Children Research Institute
  • National Institute of Allergy and Infectious Diseases
  • NYU Langone Health
  • Orange Country Research Center
  • Pan American Health Organization (PAHO)
  • Roswell Park Comprehensive Cancer Center
  • Ruprecht-Karls-University Heidelberg
  • Saudi Food and Drug Authority (SFDA)
  • St. Joseph's Hamilton
  • Stanford Cancer Institute
  • Therapeutic Goods Administration (TGA)
  • The Endocrine Society
  • The Parker Institute for Cancer Immunotherapy
  • University of British Columbia
  • University of California
  • University of Melbourne
  • University of Minnesota
  • University of Nebraska
  • University of Pennsylvania
  • University of South Alabama (USA) Mitchell Cancer Institute
  • University of Texas at Austin
  • University of Texas MD Anderson Cancer Center
  • University of Tokyo
  • USA Mitchell Cancer Center
  • World Health Organization (WHO)
  • World Intellectual Property Organization WIPO
  • World Trade Organization (WTO)
目次
Product Code: PHA0416

The global human microbiome therapeutics market is estimated to grow at a CAGR of 60.2% in the first half of the forecast period. The global human microbiome therapeutics market is estimated to reach $1bn in 2024.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 106 tables and 47 figures - all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global human microbiome therapeutics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Human Microbiome Therapeutics Market forecast from 2019-2029

Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Sector:

  • Gastrointestinal Disorders
  • Infectious Diseases
  • Metabolic Diseases
  • Dermatological Conditions
  • Other Disorders

Global Human Microbiome Therapeutics Market revenue forecast 2019-2029 by Region:

  • U.S.
  • EU5: Germany, France, U.K., Italy, Spain
  • Japan
  • Rest of the World

The human microbiome market revenue forecast 2019-2029 for the US, EU5 and Japan markets are further broken down by sector.

This report discusses the top 20 companies in the human microbiome therapeutics market:

  • 4D Pharma
  • AOBiome Therapeutics
  • C3J Therapeutics
  • Caelus Health
  • Enterome Bioscience
  • Ferring Pharmaceuticals
  • Finch Therapeutics/Crestovo
  • IGEN BIOTECH GROUP
  • Immuron
  • Intrexon Corporation
  • MaaT Pharma
  • MatriSys Biosystem
  • Microbiome Therapeutics LLC
  • Osel
  • Ritter Pharmaceuticals
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • Synthetic Biologics
  • Vedanta Biosciences

This report discusses collaborations and acquisition, recent developments, drugs developments and key pipeline products

This report lists and discusses the main pipeline products in these main sectors: gastrointestinal disorders submarket, metabolic disorders submarket, infectious diseases submarket, dermatological disorders submarket and other disorders submarket.

Qualitative analysis of the human microbiome therapeutics market in the form of a SWOT Analysis.

Key Questions Answered by this Report:

  • How is the market for human microbiome therapeutics evolving?
  • What is driving and restraining the human microbiome therapeutics market dynamics?
  • What are the market shares of the submarkets for gastrointestinal disorders, infectious diseases, metabolic diseases, dermatological conditions, and other disorders from the overall human microbiome therapeutics market?
  • How will each of the submarket segments within the human microbiome therapeutics market grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each of the submarkets within the human microbiome therapeutics market develop from 2019 to 2029?
  • Which submarkets will be the main driver of growth in the overall market from 2019 to 2029?
  • How will the regional market shares in the human microbiome therapeutics market change by 2029 and which geographical region will lead the market in 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the global human microbiome therapeutics market. You find data, trends and predictions.

Buy our report today Global Human Microbiome Therapeutics Market Forecast 2019-2029: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Human Microbiome Therapeutics: Market Overview
  • 1.2. Global Human Microbiome Therapeutics: Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. An Introduction to Human Microbiome

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
  • 2.2. Human Microbiota in Health
    • 2.2.1. Microbiome-Host Interaction
    • 2.2.2. Human Microbiota Ecosystems
  • 2.3. Human Microbiota in Disease
    • 2.3.1. Role of Microbiota in Health and Disease (Human Microbiota in Health)
  • 2.4. Microbiome Projects under development
  • 2.5. Hindrances for Microbiome as therapy
  • 2.6. Unmet needs of Microbiome

3. The Global Burden of Human Microbiome Diseases

4. Human Microbiome Therapeutics: Market Segmentation

  • 4.1. Gastrointestinal Disorders
    • 4.1.1. Classification of Gastrointestinal Disorders
    • 4.1.2. Role of Microbiota in Gastrointestinal Disorders
  • 4.2. Infectious Disorders
    • 4.2.1. Classification of Infectious Disease
    • 4.2.2. Role of Microbiota in Infectious Disease
  • 4.3. Metabolic & Liver Disorders
    • 4.3.1. Classification of Metabolic & Liver Disorder
    • 4.3.2. Role of Microbiota in Metabolic Disorders
  • 4.4. Dermatological Conditions
    • 4.4.1. Classification of Dermatological Conditions
    • 4.4.2. Role of Microbiota in Dermatological Conditions

5. Phases of Clinical Trials

6. Human Microbiome Therapeutics: Market Definition

  • 6.1. The Global Human Microbiome Therapeutics Market, 2019-2029
  • 6.2. The Global Human Microbiome Therapeutics Market: Market Overview
  • 6.3. The Global Human Microbiome Therapeutics In 2020
  • 6.4. The Global Human Microbiome Therapeutics Market Forecast 2019-2029
  • 6.5. Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029

7. Global Human Microbiome Therapeutics Market by Sector: Market Forecast 2019-2029

  • 7.1. Gastrointestinal Disorders Submarket Forecast 2019-2029
  • 7.2. Infectious Diseases Submarket Forecast 2019-2029
  • 7.3. Metabolic Diseases Submarket Forecast 2019-2029
  • 7.4. Dermatological Conditions Submarket Forecast 2019-2029
  • 7.5. Other Disorders (Cardiovascular, CNS, Cancer) Submarket Forecast 2019-2029

8. Global Microbiome Therapeutics Market Potential

  • 8.1. Microbiome Therapeutics Market Potential for GI Disorders
  • 8.2. Microbiome Therapeutics Market Potential for Infectious Disorders
  • 8.3. Microbiome Therapeutics Market Potential for Metabolic Disorders
  • 8.4. Microbiome Therapeutics Market Potential for Dermatological Conditions
  • 8.5. Microbiome Therapeutics Market Potential for Other Disorders

9. Leading National Markets for Human Microbiome Therapies: Market Forecast 2019-2029

  • 9.1. The Human Microbiome Therapeutics Market by Region
    • 9.1.1. Global Distribution of Human Microbiome Therapeutics, 2021
  • 9.2. Leading National Markets: Forecast 2019-2029
    • 9.2.1. Changing Market Shares by Region, 2019-2029
  • 9.3. United States
    • 9.3.1. The United States Human Microbiome Therapeutics Market: Market Forecast 2019-2029
    • 9.3.2. The United States Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
      • 9.3.2.1. The United States Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029
  • 9.4. EU5
    • 9.4.1. EU5 Human Microbiome Therapeutics Market: Market Forecast 2019-2029
      • 9.4.1.1. EU5 Markets: Changing Market Shares by Country, 2019-2029
    • 9.4.2. EU5 Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
      • 9.4.2.1. EU5 Human Microbiome Therapies: Changing Market Shares by Sector 2019-2029
  • 9.5. Germany
    • 9.5.1. German Human Microbiome Therapeutics Market: Market Forecast 2019-2029
  • 9.6. France
    • 9.6.1. French Human Microbiome Therapeutics Market: Market Forecast 2019-2029
  • 9.7. UK
    • 9.7.1. UK Human Microbiome Therapeutics Market: Market Forecast 2019-2029
  • 9.8. Italy
    • 9.8.1. Italian Human Microbiome Therapeutics Market: Market Forecast 2019-2029
  • 9.9. Spain
    • 9.9.1. Spanish Human Microbiome Therapeutics Market: Market Forecast 2019-2029
  • 9.10. Japan
    • 9.10.1. The Cost of Treatment in Japan
    • 9.10.2. Japanese Pharmaceutical Industry Regulatory Reform
    • 9.10.3. Japanese Human Microbiome Therapeutics Market Forecast 2019-2029
    • 9.10.4. Japan Human Microbiome Therapeutics Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
      • 9.10.4.1. Japan Human Microbiome Therapies: Changing Market Shares by Sector, 2019-2029
  • 9.11. Rest of the World
    • 9.11.1. Rest of the World Human Microbiome Therapeutics Market: Market Forecast 2019-2029

10. Leading Companies in the Human Microbiome Therapeutics Market, 2019-2029

  • 10.1. 4D Pharma Plc.
    • 10.1.1. 4D Pharma: Collaborations and Acquisitions
    • 10.1.2. 4D Pharma: Microbiome Drugs Development Pipeline, 2018
    • 10.1.3. 4D Pharma: Recent Developments
    • 10.1.4. 4D Pharma: Key Pipeline Products
  • 10.2. Synthetic Biologics
    • 10.2.1. Synthetic Biologics: Collaborations and Agreement
    • 10.2.2. Synthetic Biologics: Drug Development Pipeline, 2018
    • 10.2.3. Synthetic Biologics: Recent Developments
    • 10.2.4. Synthetic Biologics Key Pipeline Products,2018
  • 10.3. Seres Therapeutics
    • 10.3.1. Seres Therapeutics: Collaborations and Agreement
    • 10.3.2. Seres Therapeutics: Drug Development Pipeline, 2018
    • 10.3.3. Seres Therapeutics: Key Pipeline Products
  • 10.4. Ferring Pharmaceuticals
    • 10.4.1. Ferring Pharmaceuticals: Collaborations and Agreement
    • 10.4.2. Ferring Pharmaceuticals: Drug Development Pipeline, 2018
    • 10.4.3. Ferring Pharmaceuticals: Key Pipeline Products, 2018
  • 10.5. AOBiome Therapeutics
    • 10.5.1. AOBiome Therapeutics: Collaborations and Agreement
    • 10.5.2. AOBiome Therapeutics: Drug Development Pipeline, 2018
    • 10.5.3. AOBiome Therapeutics: Key Pipeline Products, 2018
  • 10.6. Osel Inc.,
    • 10.6.1. Osel Inc: Product Development Activities
    • 10.6.2. Osel Inc: Drug Development Pipeline, 2018
    • 10.6.3. Osel Inc: Key Pipeline Products, 2018
  • 10.7. Immuron Ltd
    • 10.7.1. Immuron: Collaboration and Agreement
    • 10.7.2. Immuron: Drug Development Pipeline, 2018
    • 10.7.3. Immuron: Key Pipeline Products, 2018
  • 10.8. Ritter Pharmaceuticals, Inc.
    • 10.8.1. Ritter Pharmaceuticals: Collaboration and Agreement
    • 10.8.2. Ritter Pharmaceuticals: Drug Development Pipeline, 2018
    • 10.8.3. Ritter Pharmaceuticals: Key Pipeline Products, 2018
  • 10.9. Intrexon Corporation
    • 10.9.1. Intrexon: Collaboration and Agreement
    • 10.9.2. Intrexon: Drug Development Pipeline, 2018
    • 10.9.3. Intrexon: Key Pipeline Products, 2018
  • 10.10. Synlogic
    • 10.10.1. Synlogic: Collaborations and Agreement
    • 10.10.2. Synlogic: Drug Development Pipeline, 2018
    • 10.10.3. Synlogic: Key Pipeline Products, 2018
  • 10.11. C3J Therapeutics
    • 10.11.1. C3J Therapeutics: Product Development Activities
    • 10.11.2. C3J Therapeutics: Drug Development Pipeline, 2018
    • 10.11.3. C3J Therapeutics: Key Pipeline Products, 2018
  • 10.12. Finch Therapeutics/Crestovo
    • 10.12.1. Finch/Crestovo: Collaboration and Agreement
    • 10.12.2. Finch/Crestovo: Drug Development Pipeline, 2018
    • 10.12.3. Finch/Crestovo: Key Pipeline Products, 2018
  • 10.13. MaaT Pharma
    • 10.13.1. MaaT Pharma: Collaboration and Agreement
    • 10.13.2. MaaT Pharma: Drug Development Pipeline, 2018
  • 10.14. IGEN BIOTECH GROUP
    • 10.14.1. IGEN BIOTECH: Product Development Activities
    • 10.14.2. IGEN BIOTECH: Key Pipeline Products
  • 10.15. MatriSys Biosystem
    • 10.15.1. MatriSys Biosystem: Product Development Activities
    • 10.15.2. MatriSys Biosystem: Drug Development Pipeline, 2018
    • 10.15.3. MatriSys Biosystem: Key Pipeline Products, 2018
  • 10.16. Second Genome
    • 10.16.1. Second Genome: Collaboration and Agreement
    • 10.16.2. Second Genome: Drug Development Pipeline, 2018
    • 10.16.3. Second Genome: Key Pipeline Products, 2018
  • 10.17. Microbiome Therapeutics LLC
    • 10.17.1. Microbiome Therapeutics: Product Development Activities
    • 10.17.2. Microbiome Therapeutics: Drug Development Pipeline, 2018
    • 10.17.3. Microbiome Therapeutics: Key Pipeline Products, 2018
  • 10.18. Caelus Health
    • 10.18.1. Caelus Health: Collaboration and Agreement
    • 10.18.2. Caelus Health: Drug Development Pipeline, 2018
    • 10.18.3. Caelus Health: Key Pipeline Products, 2018
  • 10.19. Enterome Bioscience
    • 10.19.1. Enterome Bioscience: Drug Development Pipeline, 2018
    • 10.19.2. Enterome Bioscience: Collaboration and Agreement
    • 10.19.3. Enterome Bioscience: Key Pipeline Products, 2018
  • 10.20. Vedanta Biosciences
    • 10.20.1. Vedanta Biosciences: Collaboration and Agreement
    • 10.20.2. Vedanta Biosciences: Drug Development Pipeline, 2018
    • 10.20.3. Vedanta Biosciences: Key Pipeline Products, 2018

11. Gastrointestinal Disorders: Key Products, 2018

  • 11.1. RBX2600 & RBX7455: Ferring Pharmaceuticals
  • 11.2. SER-109, SER287 & SER-262: Seres Therapeutics
  • 11.3. Ribaxamase & SYN-010: Synthetic Biologics
  • 11.4. IMM-529: Immuron
  • 11.5. SGM-1019: Second Genome
  • 11.6. Blautix, Thetanix & Rosburix: 4D Pharma
  • 11.7. EB8018: Enterome Bioscience

12. Metabolic Disorders: Key Products, 2018

  • 12.1. RP-G28: Ritter Pharmaceuticals
  • 12.2. IMM-124E: Immuron
  • 12.3. CP-001: Caelus Health
  • 12.4. NM504 & NM505: Microbiome Therapeutics
  • 12.5. SYNB1020: Synlogic

13. Infectious Diseases: Key Products, 2018

  • 13.1. LACTIN-V: Osel
  • 13.2. AOB-201: AOBiome Therapeutics
  • 13.3. MaaT001: MaaT Pharma
  • 13.4. CBM588: Osel Inc.

14. Dermatological Disorders: Key Products, 2018

  • 14.1. AOB101, AOB102 & AOB103: AOBiome Therapeutics
  • 14.2. MSB-01 & MSB-03: MatriSys Biosystem

15. Other Disorders: Key Products, 2018

  • 15.1. AG013: Intrexon
  • 15.2. AOB202 & AOB 203: AOBiome Therapeutics
  • 15.3. C16G2: C3J Therapeutics
  • 15.4. Microbiome Modulators: IGEN BIOTECH

16. Qualitative Analysis of the Human Microbiome Therapeutics, 2019-2029

  • 16.1. Market Factors Influencing Human Microbiome Therapeutics Market
  • 16.2. SWOT Analysis of the Global Human Microbiome Therapeutics Market, 2019-2029
    • 16.2.1. Strengths
      • 16.2.1.1. Novel & Efficient Therapies
      • 16.2.1.2. A Healthy R&D Pipeline
      • 16.2.1.3. Collaboration Among Key Industry Players
    • 16.2.2. Weaknesses
      • 16.2.2.1. Market Competition
      • 16.2.2.2. Consumer Perception
      • 16.2.2.3. Ethical Issues
      • 16.2.2.4. R&D Capabilities
      • 16.2.2.5. Knowledge Gaps
    • 16.2.3. Opportunities
      • 16.2.3.1. Growing Patient Pool
      • 16.2.3.2. Unmet Clinical Needs in Several Disease Areas
      • 16.2.3.3. Label Expansion
      • 16.2.3.4. Economic Growth in Emerging Market Provide Opportunity for Expansion
    • 16.2.4. Threats
      • 16.2.4.1. Capital Intensive Research
      • 16.2.4.2. Regulatory Approval
      • 16.2.4.3. Price
      • 16.2.4.4. Intellectual Property

17. Conclusions

  • 17.1. Overview of Current Market Conditions and Market Forecast, 2019-2029
  • 17.2. Leading Sectors in Human Microbiome Therapeutics in 2020
  • 17.3. Leading Regions in the Human Microbiome Therapeutics Market in 2020
  • 17.4. What Does the Future Hold for Microbiome Therapeutics?

Appendices

  • Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form
Back to Top